Bicycle Therapeutics plc (BCYC) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BCYC Revenue Growth
BCYC Revenue Analysis (2016–2025)
As of May 6, 2026, Bicycle Therapeutics plc (BCYC) generated trailing twelve-month (TTM) revenue of $63.5 million, reflecting significant decline in growth of -91.1% year-over-year. The most recent quarter (Q1 2026) recorded $887,000 in revenue, down 98.2% sequentially.
Looking at the longer-term picture, BCYC's 5-year compound annual growth rate (CAGR) stands at +47.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $72.6 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including CYCN (+3.7% YoY), and AGIO (+78.3% YoY), BCYC has underperformed the peer group in terms of revenue growth. Compare BCYC vs CYCN →
BCYC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BCYCCurrent | $63M | -91.1% | +47.5% | -341.3% | |
 CYCN | $2M | +3.7% | -2.0% | -239.8% | |
 AGIO | $54M | +78.3% | - | -873.9% |
BCYC Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $72.6M | +105.8% | $72.6M | 100.0% | $-247,718,000 | -341.3% |
| 2024 | $35.3M | +30.8% | $-137,691,000 | -390.3% | $-209,872,000 | -595.0% |
| 2023 | $27.0M | +86.5% | $-129,520,000 | -480.1% | $-189,946,000 | -704.1% |
| 2022 | $14.5M | +23.6% | $14.5M | 100.0% | $-116,653,000 | -806.6% |
| 2021 | $11.7M | +12.6% | $11.7M | 100.0% | $-65,618,000 | -561.0% |
| 2020 | $10.4M | -24.7% | $-22,759,000 | -219.0% | $-51,960,000 | -500.1% |
| 2019 | $13.8M | +93.4% | $-11,739,000 | -85.1% | $-26,299,000 | -190.6% |
| 2018 | $7.1M | +246.4% | $-13,625,000 | -190.9% | $-21,746,000 | -304.7% |
| 2017 | $2.1M | - | $-9,806,000 | -476.0% | $-16,213,000 | -787.0% |
| 2016 | $0 | - | $-269,289 | - | $-13,493,410 | - |
See BCYC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCYC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCYC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCYC — Frequently Asked Questions
Quick answers to the most common questions about buying BCYC stock.
Is BCYC's revenue growth accelerating or slowing?
BCYC revenue declined -91.1% year-over-year, contrasting with the 5-year CAGR of +47.5%. TTM revenue fell to $63M. This reverses the prior growth trend.
What is BCYC's long-term revenue growth rate?
Bicycle Therapeutics plc's 5-year revenue CAGR of +47.5% reflects the variable expansion pattern. Current YoY growth of -91.1% is below this long-term average.
How is BCYC's revenue distributed by segment?
BCYC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.